Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yi-Cheng Zhang

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Frontiers in Oncology|April 21, 2022
Genomic and Molecular Signatures of Successful Patient-Derived Xenografts for Oral Cavity Squamous Cell CarcinomaWei-Chen Yen, Ian Yi-Feng Chang, Kai-Ping Chang, et al.
Acta Pharmacologica Sinica|August 29, 2023
Targeting cytohesin-1 suppresses acute myeloid leukemia progression and overcomes resistance to ABT-199Wen-Xiang Ren, Hao Guo, Sheng-Yan Lin, et al.
Transplantation and Cellular Therapy|November 19, 2022
Hematopoietic Stem Cell Transplantation Activity in China 2020-2021 During the SARS-CoV-2 Pandemic: A Report From the Chinese Blood and Marrow Transplantation Registry GroupLan-Ping Xu, Dao-Pei Lu, De-Pei Wu, et al.
Bone Marrow Transplantation|November 15, 2024
Correction: Hematopoietic stem cell transplantation activity in China 2022-2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry GroupLan-Ping Xu, Pei-Hua Lu, De-Pei Wu, et al.
Bone Marrow Transplantation|September 25, 2024
Hematopoietic stem cell transplantation activity in China 2022-2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry GroupLan-Ping Xu, Pei-Hua Lu, De-Pei Wu, et al.
Bone Marrow Transplantation|December 2, 2024
Outcomes of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in patients with myeloid sarcoma: a nationwide representative multicenter studyJie Sun, Yi-Cheng Zhang, Jia Wei, et al.
Haematologica|February 1, 2024
The outcome of allogeneic hematopoietic stem cell transplantation among elderly patients with severe aplastic anemia and a predictive model from the Chinese Blood and Marrow Transplant Registry groupZheng-Li Xu, Lan-Ping Xu, Yi-Cheng Zhang, et al.
The Oncologist|October 13, 2025
Real-world effectiveness of mitoxantrone hydrochloride liposome containing regimens in acute myeloid leukemiaTie-Jun Gong, Wei-Ming Li, Li Liu, et al.
Bone Marrow Transplantation|November 26, 2024
A multifactorial risk scoring system for the prediction of early relapse in CMML patients with allo-HSCT: a nationwide representative multicenter studyJian-Ying Zhou, Yu-Xiu Chen, Hai-Long Yuan, et al.
American Journal of Hematology|June 27, 2023
Impact of a novel prognostic model on allogeneic hematopoietic stem cell transplantation outcomes in patients with CMMLJian-Ying Zhou, Song Wang, Hai-Long Yuan, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Frontiers in Oncology|April 21, 2022
Genomic and Molecular Signatures of Successful Patient-Derived Xenografts for Oral Cavity Squamous Cell CarcinomaWei-Chen Yen, Ian Yi-Feng Chang, Kai-Ping Chang, et al.
Acta Pharmacologica Sinica|August 29, 2023
Targeting cytohesin-1 suppresses acute myeloid leukemia progression and overcomes resistance to ABT-199Wen-Xiang Ren, Hao Guo, Sheng-Yan Lin, et al.
Transplantation and Cellular Therapy|November 19, 2022
Hematopoietic Stem Cell Transplantation Activity in China 2020-2021 During the SARS-CoV-2 Pandemic: A Report From the Chinese Blood and Marrow Transplantation Registry GroupLan-Ping Xu, Dao-Pei Lu, De-Pei Wu, et al.
Bone Marrow Transplantation|November 15, 2024
Correction: Hematopoietic stem cell transplantation activity in China 2022-2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry GroupLan-Ping Xu, Pei-Hua Lu, De-Pei Wu, et al.
Bone Marrow Transplantation|September 25, 2024
Hematopoietic stem cell transplantation activity in China 2022-2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry GroupLan-Ping Xu, Pei-Hua Lu, De-Pei Wu, et al.
Bone Marrow Transplantation|December 2, 2024
Outcomes of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in patients with myeloid sarcoma: a nationwide representative multicenter studyJie Sun, Yi-Cheng Zhang, Jia Wei, et al.
Haematologica|February 1, 2024
The outcome of allogeneic hematopoietic stem cell transplantation among elderly patients with severe aplastic anemia and a predictive model from the Chinese Blood and Marrow Transplant Registry groupZheng-Li Xu, Lan-Ping Xu, Yi-Cheng Zhang, et al.
The Oncologist|October 13, 2025
Real-world effectiveness of mitoxantrone hydrochloride liposome containing regimens in acute myeloid leukemiaTie-Jun Gong, Wei-Ming Li, Li Liu, et al.
Bone Marrow Transplantation|November 26, 2024
A multifactorial risk scoring system for the prediction of early relapse in CMML patients with allo-HSCT: a nationwide representative multicenter studyJian-Ying Zhou, Yu-Xiu Chen, Hai-Long Yuan, et al.
American Journal of Hematology|June 27, 2023
Impact of a novel prognostic model on allogeneic hematopoietic stem cell transplantation outcomes in patients with CMMLJian-Ying Zhou, Song Wang, Hai-Long Yuan, et al.
Pageof 6